Clinical Trial Update: Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy

View source ↗

Summary

A completed clinical trial evaluating a multimodal model that predicts treatment efficacy and the risk of checkpoint inhibitor pneumonitis in advanced non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: NSCLC | Status: COMPLETED